Every Form 4 that AIM IMMUNOTECH INC (AIMI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AIMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMI filings page.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. The preferred stock position was reduced to zero, and his directly held common stock increased to 63,922 shares following the transaction.
AIM ImmunoTech Inc. director David I. Chemerow converted preferred stock into common shares. He converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock through a derivative conversion at no stated cash price. A footnote explains each preferred share is convertible into 1,000 common shares, effectively valuing the conversion at $1.00 per common share. Following the conversion, he directly holds 28,441 shares of AIM ImmunoTech common stock, with no remaining Series G preferred shares reported.
AIM ImmunoTech director David I. Chemerow reported new derivative holdings tied to a rights offering. He now holds 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued through a subscription right in a rights offering.
He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly holds 3,441 shares of common stock, alongside the preferred shares and warrants.